Stay updated on ARCHES-2 Study: ARO-ANG3 Clinical Trial
Sign up to get notified when there's something new on the ARCHES-2 Study: ARO-ANG3 Clinical Trial page.

Latest updates to the ARCHES-2 Study: ARO-ANG3 Clinical Trial page
- Check5 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe study details page now returns a 403 Forbidden response, blocking access to the usual NCT04832971 content and leaving a generic error page instead.SummaryDifference0.5%

- Check26 days agoChange DetectedAccess to the study record now shows a 403 Forbidden page with a Home button, replacing the previous study details. This indicates a site access restriction rather than a change to the study information.SummaryDifference19%

- Check47 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6, indicating a minor site update rather than changes to study content.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page's revision label has been updated to v3.6.5, indicating a minor metadata update. There are no evident changes to the study details or content.SummaryDifference17%

- Check76 days agoChange DetectedAdded a citation for Longer-Term Efficacy and Safety of Zodasiran in Patients with Mixed Hyperlipidaemia to the Publications section. This links ARCHES-2 to recent literature on the drug's long-term efficacy and safety.SummaryDifference0.0%

Stay in the know with updates to ARCHES-2 Study: ARO-ANG3 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARCHES-2 Study: ARO-ANG3 Clinical Trial page.